For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
If you continue without changing your cookie settings, we'll assume you’re happy with this.
Join Dr Paul Wylie, Director of Multiplex, Kits and Assay at Abcam, as he discusses how FirePlex® Multiplexed Assays can be employed in biomarker discovery and screening.
Learn about the unique benefits and features FirePlex® immunoassays offer, including the ability to measure up to 10 protein analytes in a highly automated high-throughput format.
Dr Paul Wylie has over 20 years of experience working in Life Sciences, with a focus in delivering solutions for early drug discovery research, particularly in HTS, using phenotypic screening and other multiplexed tehcniques. He is now the Director of Multiplex at Abcam, with responsibility for leading the strategy and implementation of Abcam's multiplex portfolio.